Wednesday, September 27, 2017

Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents

Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents
Article Summary @ GastroHep
Reasons for lack of treatment included waiting for newer therapy, co-morbidities and alcohol/drug abuse. Dr Kanwal's team comments, "Half of patients with established HCV care were followed-up in the direct-acting anti-virals era and only 29% received DAAs."

Alimentary Pharmacology & Therapeutics
ORIGINAL ARTICLE

Full Text Article:  Available Online

Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents
Authors M. Lin, J. Kramer, D. White, Y. Cao, S. Tavakoli-Tabasi, S. Madu, D. Smith, S. M. Asch, H. B. El-Serag, F. Kanwal

First published: 26 September 2017
DOI: 10.1111/apt.14328

Summary
Background
Direct-acting anti-virals (DAA) are safe, effective treatment of hepatitis C virus (HCV). Suboptimal linkage to specialists and access to DAAs are the leading barriers to treatment; however, data are limited.

Aim
To determine predictors of follow-up, receipt of DAAs, and reasons for the lack thereof.

Methods
We used clinical data from retrospective cohort of HCV-infected patients with previously established HCV care in the US Department of Veterans Affairs to examine predictors of follow-up in HCV clinics and DAA treatment (during 12/1/2013-4/30/2015). We then conducted a structured review of medical charts of HCV patients to determine reasons for lack of follow-up and treatment.

Results
We identified 84 221 veterans who were previously seen in HCV clinics during the pre-DAA era. Of these, 47 165 (56.0%) followed-up in HCV specialty clinics, 13 532 (28.7%) of whom received DAAs. Older age, prior treatment, presence of cirrhosis or HCC, HIV/HBV co-infection and psychiatric illness were predictors of follow-up. Alcohol/drug abuse and medical co-morbidity were predictors of lack of treatment. Of the 905 prospectively recruited patients, 56.2% patients had a specialist visit and 28% received DAAs. Common reasons for lack of follow-up were relocation (n = 148, 37.4%) and missed/cancelled appointments (n = 63, 15.9%). Reasons for lack of treatment included waiting for newer therapy (n = 99, 38.8%), co-morbidities (n = 66, 25.9%) and alcohol/drug abuse (n = 63, 24.7%).

Conclusions
Half of patients with established HCV care were followed-up in the DAA era and only 29% received DAAs. Targeted efforts focusing on patient and system-levels may improve the reach of treatment with the new DAAs.

No comments:

Post a Comment